Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Peter Almond finished a trial for Donanemab in September having been on the drug for three years. Donanemab is one of the new ...

The full data from the TRAILBLAZER-ALZ 2 trial of Eli Lilly’s amyloid drug donanemab has confirmed the top-line results reported in May, but also new findings that reinforce its benefits in ...

The drug Donanemab has been found to slow the progression of Alzheimer’s disease. Despite this is has been rejected for ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...

Donanemab has been hailed 'a new hope' in the fight against dementia, after research suggested it slowed the memory-robbing illness in its early stages. Now, one London clinic has become the ...

New drug approvals and a federal dementia care pilot program among the year's significant developments, according to the ...

University Hospitals Brain Health & Memory Center is now treating patients with KISUNLA™ (donanemab), a Food and Drug Administration-approved medication for the treatment of Alzheimer’s disease. UH is ...

The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...

A London clinic has become the first in Europe to roll out two Alzheimer’s wonder drugs privately after they were rejected ...

The United Kingdom medicines authority approved the Alzheimer’s disease drug Kisunla (donanemab) last week for certain patients. This follows the Unites States Food and Drug Administration ...

Donanemab and Lecanemab for Early Alzheimer’s: What You Need to Know Donanemab (Kisunla) and lecanemab (Leqembi) slow early-stage Alzheimer’s progression by targeting beta-amyloid ...